CVR 26415365Private limited company (ApS)Virksomhedsrådgivning og anden rådgivning om driftsledelse (702200)HolteFounded 21 Dec 2001
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about TJ BIOTECH HOLDING ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
1
CVR, 2020
Gross profit
957.2K
DKK, annual report 2019
-0.6% on 2018
Result
+347.5K
DKK, annual report 2019
Equity
18.3M
DKK, annual report 2019
Thomas Engelbrecht Nordkild Jonassen100% of capital and votes, until 14 Dec 2020
Thomas Engelbrecht Nordkild Jonassenuntil 14 Dec 2020
No current owner is registered.
100% of capital and votes19 Apr 2002 to 14 Dec 2020
TJ BIOTECH HOLDING ApS holds no Danish company now.
Danish companies held at 5% or more, from the CVR owner register (ejerregister), and their holdings one level down. Foreign holdings are not in CVR.
CVR 3823821310% to under 15% of capital and votes28 Nov 2016 to 13 Dec 2020
CVR 3785240615% to under 20% of capital and votes4 Jul 2016 to 13 Dec 2020
CVR 35243798100% of capital and votes15 May 2013 to 2 Dec 2020
CVR 3445997533.3% to under 50% of capital and votes14 Aug 2012 to 12 Apr 2016
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
CVR lists no current officers for this company.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
Dec 2020, monthly: 1 employee, 0 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Nov 2016 | Dec 2016 | Mar 2017 | May 2017 | Sep 2017 | Oct 2017 | Nov 2017 | Dec 2017 | Jan 2018 | Feb 2018 | Mar 2018 | Apr 2018 | May 2018 | Jun 2018 | Jul 2018 | Aug 2018 | Sep 2018 | Oct 2018 | Nov 2018 | Jan 2019 | Feb 2019 | Mar 2019 | Apr 2019 | May 2019 | Jun 2019 | Jul 2019 | Aug 2019 | Sep 2019 | Oct 2019 | Nov 2019 | Dec 2019 | Jan 2020 | Feb 2020 | Mar 2020 | Apr 2020 | May 2020 | Jun 2020 | Jul 2020 | Aug 2020 | Sep 2020 | Oct 2020 | Nov 2020 | Dec 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| FTE | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Series | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group. CVR changed its monthly method in Oct 2019: a step there need not be real.
Source: CVR, latest Dec 2020, published 23 Feb 2021.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2019, DKK: Gross profit 957.2K, Operating profit -170.7K, Result for the year 347.5K
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2019, DKK: Total assets 18.8M, Equity 18.3M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|
| Gross profit | -12 | 886 | 944 | 963 | 957 |
| Operating profit | -12 | +586 | -36 | -239 | -171 |
| Result for the year | -95 | +12,884 | +4,233 | +802 | +347 |
| Equity | 34 | 12,918 | 17,151 | 17,953 | 18,300 |
| Total assets | 192 | 13,312 | 17,713 | 18,351 | 18,767 |
| Employees (average) | Not reported | 1 | 1 | 1 | 1 |
| Credit metrics (Dandex calculations) | |||||
| Gross profit growth (vækst i bruttofortjeneste) | n.m.note 1 | n.m.note 1 | 6.5% | 2.1% | -0.6% |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Employee growth (vækst i antal ansatte) | Not reportednote 2 | n.m.note 1 | 0% | 0% | 0% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
How each credit metric is calculated:
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for TJ BIOTECH HOLDING ApS:
Have Pro? Sign in.
Amounts in DKK. Cash price is per DKK 1 of nominal capital, which a share split does not move. Implied value is the whole capital after the step at its cash price, not a valuation.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseCashPaid in 15,000, cash price 150.00, implied value 18,765,000 | 150.00 | 15,000 | 18,765,000 | 125,100 | |
| FoundingNot read from the announcement | None | None | None | 125,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Demerger (spaltning), as the demerged company (indskydende selskab)
Merger (fusion), as the continuing company (fortsættende selskab)
Source: CVR, read 18 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 18 Nov 2026.
8 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående spaltning. Kapitalejerne har i enighed besluttet, at der ikke skal udarbejdes en spaltningsplan. Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i de deltagende virksomheder må antages at være tilstrækkeligt sikrede efter spaltningen.
Virksomheden er d. 14.12.2020 opløst ved spaltning. Aktiver og gæld er som helhed overdraget til CVR-nummer 41953616 TJ Biotech Holding ApS og CVR-nummer 41953608 TJ Biotech Holding II ApS.
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående fusion. Kapitalejerne har i enighed besluttet, at der ikke skal udarbejdes en fusionsplan. Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i de deltagende selskaber må antages at være tilstrækkeligt sikrede efter fusionen.
Virksomheden er fusioneret med CVR-nummer: 35243798 TENJ BIOTECH ApS, der samtidigt er opløst.
Revision:
Udtrådt af revisionen:
DELOITTE STATSAUTORISERET REVISIONSAKTIESELSKAB, den 13.10.2011.
Indtrådt i revisionen:
DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB, Åboulevarden 31, 8000 Aarhus C, den 13.10.2011.
Ved kommunalreformen den 1. januar 2007 er hjemstedskommunen ændret.
Ny adresse:
Pile Alle 20, 2840 Holte.
Ny kommune:
Søllerød.
Revision:
Udtrådt af revisionen:
STATSAUTORISERET REVISIONSANPARTSSELSKAB BRUNO JENSEN REVISION.
Indtrådt i revisionen:
DELOITTE & TOUCHE STATSAUTORISERET REVISIONSAKTIESELSKAB, c/o Arosgården, Åboulevarden 31, 8000 Århus C.
Vedtægter ændret:
04.04.2002.
Kapitalforhøjelse:
kr. 100,00 indbetalt kontant, kurs 15.000,00.
Kapitalen udgør herefter kr. 125.100,00.
Stiftelsesdato:
21.12.2001.
Seneste vedtægtsdato:
21.12.2001.
Kapital:
kr. 125.000,00.
Indbetalingsmåde:
kontant kr. 125.000,00 til kurs 103,00.
Stifter:
Thomas Engelbrecht Nordkild Jonassen, den 21.12.2001.
Direktion:
Thomas Engelbrecht Nordkild Jonassen, den 21.12.2001.
Selskabet tegnes af en direktør.
Revision:
CVR-NR. 26108632 STATSAUTORISERET REVISIONSANPARTSSELSKAB BRUNO JENSEN REVISION, Slotsmarken 12, 1. th., 2970 Hørsholm, den 21.12.2001.
Første regnskabsår:
21.12.2001 - 31.12.2002.
Regnskabsår:
01.01 - 31.12.
P-number 1008884206Pile Alle 20, 2840 Holte